Advance Care Planning and Care Coordination for People With Parkinson's Disease and Their Family Caregivers - Study Protocol for a Multicentre, Randomized Controlled Trial by Faber, M.J. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2021-11-05 and may be subject to
change.
STUDY PROTOCOL
published: 05 August 2021
doi: 10.3389/fneur.2021.673893
Frontiers in Neurology | www.frontiersin.org 1 August 2021 | Volume 12 | Article 673893
Edited by:
Marianne De Visser,
University of Amsterdam, Netherlands
Reviewed by:
Martin Klietz,










This article was submitted to
Neurocritical and Neurohospitalist
Care,
a section of the journal
Frontiers in Neurology
Received: 28 February 2021
Accepted: 30 June 2021
Published: 05 August 2021
Citation:
Meinders MJ, Gentile G, Schrag AE,
Konitsiotis S, Eggers C, Taba P,
Lorenzl S, Odin P, Rosqvist K,
Chaudhuri KR, Antonini A, Bloem BR
and Groot MM (2021) Advance Care
Planning and Care Coordination for
People With Parkinson’s Disease and
Their Family Caregivers—Study




Advance Care Planning and Care
Coordination for People With
Parkinson’s Disease and Their Family
Caregivers—Study Protocol for a
Multicentre, Randomized Controlled
Trial
Marjan J. Meinders 1,2*, Giovanni Gentile 3, Anette E. Schrag 4, Spiros Konitsiotis 5,
Carsten Eggers 6,7, Pille Taba 8,9, Stefan Lorenzl 10,11,12, Per Odin 13, Kristina Rosqvist 13,
K. Ray Chaudhuri 14, Angelo Antonini 3, Bastiaan R. Bloem 2 and Marieke M. Groot 15
on behalf of PD_Pal consortium
1 Scientific Center for Quality of Healthcare, Radboud Institute for Health Sciences, Radboud University Medical Center,
Nijmegen, Netherlands, 2Department of Neurology, Center of Expertise for Parkinson and Movement Disorders, Donders
Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, Netherlands, 3Department of
Neuroscience, University of Padua, Padua, Italy, 4Department of Clinical and Movement Neurosciences, UCL Institute of
Neurology, University College London, London, United Kingdom, 5Department of Neurology, Medical School, University of
Ioannina, Ioannina, Greece, 6Department of Neurology, Philipps University Marburg, Marburg, Germany,
7 Knappschaftskrankenhaus Bottrop GmbH, Department of Neurology, Bottrop, Germany, 8Department of Neurology and
Neurosurgery, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia, 9Neurology Clinic, Tartu University Hospital,
Tartu, Estonia, 10 Institute of Nursing Science and Practice, Paracelsus Medical University, Salzburg, Austria, 11Department of
Neurology and Department of Palliative Care, Ludwig-Maximilians-University, Munich, Germany, 12Department of Neurology,
Klinikum Agatharied, Hausham, Germany, 13Division of Neurology, Department of Clinical Sciences Lund, Lund University,
Lund, Sweden, 14Department of Basic and Clinical Neuroscience, Parkinson’s Foundation Centre of Excellence, King’s
College London, London, United Kingdom, 15Department of Anesthesiology, Pain and Palliative Care, Radboud University
Medical Center, Nijmegen, Netherlands
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disease with
motor- and non-motor symptoms. When the disease progresses, symptom burden
increases. Consequently, additional care demands develop, the complexity of treatment
increases, and the patient’s quality of life is progressively threatened. To address these
challenges, there is growing awareness of the potential benefits of palliative care for
people with PD. This includes communication about end-of-life issues, such as Advance
Care Planning (ACP), which helps to elicit patient’s needs and preferences on issues
related to future treatment and care. In this study, we will assess the impact and feasibility
of a nurse-led palliative care intervention for people with PD across diverse European
care settings.
Methods: The intervention will be evaluated in a multicentre, open-label randomized
controlled trial, with a parallel group design in seven European countries (Austria, Estonia,
Germany, Greece, Italy, Sweden and United Kingdom). The “PD_Pal intervention”
comprises (1) several consultations with a trained nurse who will perform ACP
conversations and support care coordination and (2) use of a patient-directed “Parkinson
Support Plan-workbook”. The primary endpoint is defined as the percentage of
participants with documented ACP-decisions assessed at 6 months after baseline (t1).
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Secondary endpoints include patients’ and family caregivers’ quality of life, perceived
care coordination, patients’ symptom burden, and cost-effectiveness. In parallel, we
will perform a process evaluation, to understand the feasibility of the intervention.
Assessments are scheduled at baseline (t0), 6 months (t1), and 12 months (t2). Statistical
analysis will be performed by means of Mantel–Haenszel methods and multilevel logistic
regression models, correcting for multiple testing.
Discussion: This study will contribute to the current knowledge gap on the application
of palliative care interventions for people with Parkinson’s disease aimed at ameliorating
quality of life and managing end-of-life perspectives. Studying the impact and feasibility
of the intervention in seven European countries, each with their own cultural and
organisational characteristics, will allow us to create a broad perspective on palliative
care interventions for people with Parkinson’s disease across settings.
Clinical Trial Registration: www.trialregister.nl, NL8180.
Keywords: Parkinson’s disease, palliative care, advance care planning, care coordination, family caregiver
INTRODUCTION
Parkinson’s disease (PD) is the second most common
neurodegenerative disease worldwide, affecting 1–2% of the
world population above 65 years of age. The number of people
with PD is expected to double from 6.9 million in 2015 to 14.2
million in 2040 (1). On average, people live for 15 years with
the disease (2–4). As the disease progresses, people develop a
range of motor as well as non-motor symptoms, which typically
increase over time. For example, in a European cohort of 692
people diagnosed with late-stage PD and an average disease
duration of 15 years, 68% reported off-periods for at least 50%
of the day, 82% reported falls, and 92% experienced at least one
neuropsychiatric symptom, with apathy, depression, and anxiety
most commonly being present (5, 6). Furthermore, around
60% of patients with PD will ultimately develop dementia
(7, 8). In light of this complex and multifaceted phenotype,
it is understandable that treatment programs are complex,
that quality of life becomes progressively threatened, and that
informal carers experience considerable distress. However,
despite the very high symptom burden at the end of life, end-of-
life care in the field of PD often is not aligned with patients’ needs
and preferences (9, 10). Palliative care is often not introduced:
in a cohort of advanced PD patients in Germany, with a mean
disease duration of 17 years, 72% of the participants expressed
an unmet need for palliative care (11). A large study including
∼125,000 people with PD showed that 43% died in a hospital and
only 9.7% in their homes, which is substantially lower compared
to the 17% of the general elderly population dying at home.
Hospice services were barely utilized, that is, in only 0.6% of the
patients (12).
To address these challenges, there is growing awareness
of the potential benefits of palliative care for people with
PD (13, 14). According to the World Health Organization
definition, published in 2012, palliative care is “an approach
that improves the quality of life of patients and their families
facing the problems associated with life threatening illness,
through the prevention and relief of suffering by means of early
identification and impeccable assessment and treatment of pain
and other problems, physical, psychosocial and spiritual” (15).
Advance Care Planning (ACP) is a cornerstone for palliative care,
involving the timely identification and definition of goals as well
as preferences for future medical treatment and care, discussion
of these goals and preferences with family and healthcare
providers, and recording and reviewing of these preferences
if appropriate (16). There is a vast amount of international
evidence, particularly in the field of oncology, on the benefits of
palliative care in improving quality of life, increasing satisfaction
with care and, for some patients, prolonging life (17–19).
Although the importance of palliative care for chronic
neurological conditions has been well-established in the setting
of clinical studies (13, 20, 21), in real life, many PD patients
do not receive the support they need. Unlike conditions that
are life-threatening immediately after diagnosis, the sense of
urgency seems to be lacking in a slowly progressive and long-
lasting condition like PD. The unpredictable prognosis makes
it difficult to define a clear referral cutoff point, which prevents
neurologists from appropriately referring patients to specialist
palliative care services. Moreover, many physicians lack the
communication skills and do not want to take away hope
and patience (22). PD patients’ acceptance of their symptoms
as part of their everyday life, believing that no effective
treatments are available, is an important barrier to report non-
motor symptoms (23), hampering the recognition of palliative
care needs.
Only recently, several studies have explored how palliative
care principles should be designed and implemented to effectively
support and treat people with PD (24–28). Foremost, effective
palliative care requires an individualized approach, and patients
should actively be invited to discuss ACP early on in the course of
the disease and on a regular basis; palliative care requires skilled
professionals who are knowledgeable on both PD and palliative
care, and ACP decisions should be clearly documented and
shared with relevant services. Finally, given the multidisciplinary
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nature of palliative care, care coordination should be an explicit
responsibility of the care team (24, 29, 30).
Further studies are needed to evaluate the positive effects of
palliative care models across a range of healthcare systems. The
current PD_Pal trial was designed to understand the impact of
palliative care services for PD, within a wide range of European
healthcare systems. An evidence-based intervention will be
evaluated consisting of a nurse-led, person-centred palliative
care model for people with PD living at home, assisted living
situation, or nursing homes. The intervention deals with two
major challenges that many people with PD encounter (31, 32):
1. Increasing risk of cognitive and/or communication
impairments that hinder the ability to easily discuss or
indicate preferences about healthcare and quality of life when
the disease advances. Therefore, timely documentation of
patients’ wishes related to advanced and end-of-life care is
essential, but rarely part of standard care.
2. The lack of care coordination during the transition from
clinic-based care (focused on adjusting patients’ medical
treatment to control symptoms) to community-based care
(focused on adjusting patients’ care and daily living routines
to comfortably live with the symptoms that can no longer be
completely controlled).
The objective of this study is two-fold. First, we will determine
the effectiveness of a nurse-led, person-centred palliative care
intervention for people with PD and their family caregivers
compared to care as usual. To evaluate this intervention, we
will primarily focus on ACP documentation in the medical
files, to demonstrate that relevant end-of-life issues were indeed
discussed. Additional outcomes will focus on patients’ clinical
outcomes, caregivers’ quality of life, patients’ and caregivers’ costs
and service utilisation. Second, we will assess the feasibility of the
PD_Pal intervention across seven European countries (Austria,
Estonia, Germany, Greece, Italy, Sweden and United Kingdom).
METHODS AND ANALYSIS
Study Design
The intervention will be evaluated in a multicentre, single-
blinded randomized controlled parallel group design, in seven
European countries. Within each participating country, one trial
centre will lead the recruitment. Participants will be randomized
in a 1:1 ratio to either the intervention or the control group,
who will receive care as usual. The intervention will be delivered
during the first 6 months after randomisation. Assessments will
be performed at baseline (t0), at the end of the intervention phase,
that is, after 6 months (t1), and after 12 months (t2) for follow-up
(see Figure 1).
Participating clinical centres should have at least one
movement disorder specialist available. Centres are excluded if
they already apply a palliative care model as part of their routine
care workflow; if they have detailed palliative care guidelines
available with corresponding high-quality practices; and/or if the
centre is participating or has participated in a palliative care study
in the past 3 years.
Study Population
The intervention targets individuals diagnosed with idiopathic
PD or an atypical parkinsonism syndrome, independent of
their age.
In order to be eligible to participate in this study, a person
should meet all of the following criteria:
1 Meeting the clinical diagnostic criteria for PD, as defined by
the Movement Disorders Society (33), or the criteria for an
atypical parkinsonism syndrome (34);
2 Hoehn & Yahr≥3 (35);
3 Progressive deterioration in physical and/or cognitive function
despite optimal therapy, according to the primary physician;
4 Cognitively able to complete questionnaires and to participate
in interviews;
5 Ability to provide written informed consent; and
6 Availability of a family caregiver or informal caregiver, jointly
abbreviated as “FC” in the remainder of this article.
Furthermore, persons are excluded from participation if one of
the following criteria are met:
1 Inability to communicate independently, with or without
supportive communication tools;
2 Unable or unwilling to commit to study procedures;
3 Presence of additional chronic medical illnesses which may
require palliative services (e.g., metastatic cancer);
4 Already receiving palliative care or hospice services; and/or
5 Already participating in a clinical study for palliative care.
Having a device-assistant advanced treatment [including deep
brain stimulation (DBS), levodopa–carbidopa intestinal gel
(LCIG), and continuous subcutaneous apomorphine infusion
(CSAI)], or considering one, is not an exclusion criterion.Wewill
identify patients who certainly have complex medical needs and
at the same time are still able to commit to ACP conversations
and make decision.
The participation of a FC is compulsory. The FC should meet
the following criteria:
1 Willing to provide written informed consent;
2 Cognitively able to complete questionnaires and to participate
in interviews;
3 Aging ≥ 18 years; and
4 Identified by the person with PD as the FC.
Sample Size Calculation
We assume that 5% of the target population will have
documented ACP wishes at baseline. The study is powered to
show a 20% absolute increase from a baseline of 5% (control
group) in the primary outcome measure, that is, documented
ACP-decisions, at 6 months, with a power of 0.80, a statistical
significance of 0.05 (two sided) and an intraclass correlation
coefficient (correcting for clustering within countries) of 0.10,
by a Fisher’s exact test. With the above assumptions, 74 patients
in each treatment group are required. The sample size will be
increased to 93 patients in each treatment group for allowing a
25% dropout rate within the 6-month follow-up period for the
primary outcome effectiveness evaluation.
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FIGURE 1 | Study flowchart of the PD_Pal clinical trial.
PD_Pal Intervention
The proposed PD_Pal intervention is the result of a systematic
approach, where we first explored the views of healthcare
professionals and patients on palliative care in the Netherlands
(25, 36, 37). Subsequently, these findings were translated into
the intervention: trained nurses and a workbook for patients.
The specifically trained nurses, labelled as PD_Pal nurses in this
study (see below), will be coordinating transmural, integrated,
and proactive palliative care, including ACP, through regular
conversations with patients and their FC. The conversations are
supported with a patient-directed “Parkinson Support Plan—
workbook,” designed to be used at home by the patient and FC to
document their wishes and preferences related to end-of-life care,
to prepare and guide the conversations with the PD_Pal nurse.
The plan is structured within four steps (Table 1). These steps
are based on previous theories [e.g., ACP (16)], shared-decision
making (38), The Chronic CareModel (39), and empirical studies
[e.g., interventions guiding ACP conversations that describe
healthcare models or interventions aimed to provide care aligned
with patients’ needs, values, and preferences on all domains
of palliative care, for example, physical, social, psychological,
spiritual, and financial (40–43)]. The initial workbook was
reviewed by a panel of five Dutch patients and caregivers and
subsequently adapted based on their feedback. To make the
workbook suitable for the international study, the PD_Pal nurse
training started with a critical review of the workbook, and
adapted to the national situation, where needed. Given the
comprehensive scope of the workbook, the intervention goes
beyond the clinical management of PD consequences.
The PD_Pal Nurse
The PD_Pal nurses are trained to assist the participating
patients in taking the four steps of the Parkinson Support Plan.
The training consists of (1) face-to-face sessions to develop
skills necessary to assist the patient during the intervention,
including skills to deal with emotions, and (2) monthly digital
coaching sessions with the intervention-coordinator (MMG)




Describe current health and caregivers, and identification
of current needs related to care and care coordination.
2—Proactive care
plan
Identify expected future challenges and care needs per
domain (e.g., physical, social, psychological, spiritual,
and financial). The leading theme in this step is: “What is
needed for good care, now and in the future?” There is
also attention for challenges and needs, as experienced




Identify and document the patient’s ideas about quality
of life, and preferences related to end-of-life care (e.g.,
surrogate decision maker; life prolonging procedures;
and hospital or nursing home admissions).
4—Coordination
and revision plan
Discuss and plan how the “Parkinson Support Plan” will
be coordinated and reviewed in the future (e.g., contact
(newly assigned if not already assigned) care coordinator,
update him/her about the plan, and facilitate him/her in
consulting a Parkinson expert when necessary; decide
when and how the “Parkinson Support Plan” will be
reviewed). The PD_Pal nurse and the dyad will allocate
the referred to the assigned care coordinator, to
guarantee continuity of the integrated palliative care
beyond the PD_Pal study.
where experiences can be discussed. Nurses will be selected based
on the following criteria:
1 Previous experience in nursing (preferably on a “Bachelor of
Nursing” or comparable level);
2 Experienced in delivering care for people with Parkinson’s
disease and/or atypical parkinsonism syndromes OR
experienced in delivering palliative care;
3 Being able to visit patients at home/at a clinical centre;
4 Able to speak and write in English (training will be held
in English);
5 Being able or willing to talk about the end of life; and
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6 Open attitude toward (differences in) patients’ preferences and
values in life.
The delivery of the intervention (e.g., setting, timing, frequency,
and content) will be tailored as much as possible to the patient’s
and FC’s preferences and possibilities. Although the duration
of the total intervention is tailored to patients’ preferences, the
study design and timeline mandate the following limits: the first
conversation with the PD_Pal nurse should be scheduled up to
4 weeks after randomisation and the last conversation up to 6
months after the randomisation.
The Control Group
Patients in the control arm receive care-as-usual from their
neurology and/or home care team. The care-as-usual and the
extent to which ACP is part of this care are expected to differ
among the participating countries.
Recruitment and Consent
Several methods to reach the target group are employed, building
upon the experiences with patient recruitment in the Care
for Late Stage Parkinsonism (CLaSP) study (5, 44). First of
all, the participating neurology clinics recruit participants from
their outpatient and inpatient clinics and registries of patients
who have indicated to be interested in research participation.
Neurology clinics can only act as a recruitment centre if they
do not offer palliative care services themselves. Second, the
study centres will contact geriatricians, general practitioners,
nursing homes, patient advocate groups, and self-help groups
to draw attention to the project and identify and recruit eligible
patients. Identified clinicians give written information to patients
about the study, and if patients are interested and willing, the
clinician completes a standard referral form and sends it to
the local research team. The research team will contact the
patient by phone, explain the trial, check the eligibility criteria
as far as possible in a phone call, and will send the full
information package. Patients will have at least 1 week to consider
participation. If a patient provides verbal consent to contact their
FC, the research team will approach the FC and invite the FC for
participation as well, following the same procedure as outlined
for the patient.
Patients who are interested in participation, meet the selection
criteria, and have provided their initial, verbal consent will be
given a first appointment for a screening visit with a study
assessor, which could be a physician (neurologist, geriatrician,
or psychiatrist), study nurse, or trained researcher. During the
screening visit, information about the study will be explained
again, and if the participant still agrees, the informed consent
form will be signed. Subsequently, eligibility criteria will be
verified in the screening visit, before collecting any baseline
clinical and demographic data. In case the eligibility criteria
can be verified based on a telephone interview and review of
the medical records, written informed consent will be obtained
without a screening visit. All participants will be able to withdraw
their informed consent to parts or to the overall participation at
any point in time.
Randomisation, Blinding, and Treatment
Allocation
Participants are considered to be enrolled into the study
following written informed consent, confirmation of eligibility,
and allocation of the participant ID number. After inclusion,
a patient will participate in the baseline assessment (t0), after
which the patient will be randomized to either the intervention
or the control group (1:1) by a computer-generated algorithm
embedded within the certified eCRF system. A member of the
research team will communicate to the patient and FC the group
to which they have been assigned.
The trial is single-blinded, as patients and their FCs cannot
be blinded for treatment allocation. Participants are urged not
to discuss their allocation status with the blinded study assessor,
who is responsible for the data collection. At each visit, the
assessor will record to which study arm they think the participant




The primary endpoint is defined as the percentage of participants
with documented ACP decisions in at least one of the patients’
medical records assessed at 6 months (t1) after baseline. We
believe it is important to choose an outcome measure that
is as close as possible to the intervention. The choice of
documentation of ACP decisions as the primary endpoint was
prompted by a number of considerations. One of these is that
even though discussing ACP is a crucial part of the intervention,
such a discussion by itself does not ensure better care, and
adequate documentation is therefore a further prerequisite.
Another consideration is that this endpoint proved to be
sensitive to change in similar interventions targeting other
populations (40).
Secondary Endpoints
Secondary endpoints relate to the expectation that patients and
their FCs will experience a better quality of life, improved
care coordination, and a reduced patient symptom burden and
that FC will experience an improved quality of life, in a cost-
effective manner.
Other Endpoints
To characterize the population, we will collect demographic and
social information from the participants. Furthermore, we will
evaluate the feasibility aspects of the intervention and we will
document what is needed to tailor the intervention procedures
and materials to country-specific characteristics (e.g., differences
in language and organisation of care).
In those participants enrolled in the trial who provide a
separate consent, wearable sensor data will be collected, by
using the PDMonitor system. The PDMonitor system consists
of five devices which will be attached to both shanks and wrists
and the lower back. Each device contains an accelerometer,
a gyroscope, and a magnetometer. The PDMonitor is a CE-
marked product, certified as Medical Device class IIa. The
system has been validated for PD-related motor-symptoms,
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for example, bradykinesia, dyskinesia, tremor, freezing of gait,
gait disturbances, postural instability, ON/OFF conditions, and
response fluctuations (45, 46). In PD_Pal, data will be recorded
during daily living after baseline (t0), and after each follow-up
visit (t1 and t2), for five consecutive days (morning to evening)
for a maximum of 12 h per day. The data will be used for further
validation and exploratory analysis, for example to see if the data
can serve as a predictor for the primary and secondary outcomes
(e.g., how activity level and severity motor symptoms measured
at home are related to the frequency of ACP arrangements, or
patients’ and caregivers’ quality of life).
Assessment Scheme
The baseline assessment (t0) consists of an in-person interview
performed by the study assessor. The baseline assessment takes
place either in the outpatient clinic setting, at the patient’s home,
or remotely via a video connection. In addition, the patient and
FC complete a set of questionnaires that are self-administered.
Within 2 weeks after the baseline assessment, a participant is
randomized to either the intervention or the control group. For
all participants, two follow-up assessments are thereafter foreseen
(t1 and t2). After completion of the t2 assessment, the patient
and FC will be invited for an optional semi-structured interview
about end-of-life issues. Table 2 presents all assessments and the
instruments that will be used to evaluate the (cost-)effectiveness
and feasibility of the PD_Pal intervention.
Statistical Analysis
Primary Endpoint
To evaluate the effectiveness of the intervention, all analyses
of endpoints will be done in the intent-to-treat population.
The primary efficacy analysis will be to investigate the effect
of the PD_Pal intervention on the percentage of patients with
documented ACP decisions from baseline to month 6 in the
intervention and care-as-usual group. This will be tested by
means of the Mantel Haenszel estimate method and by using
multilevel logistic regression model, with data clustered within
countries and with categorical factors (groups) and baseline
characteristics as covariates, in order to test which independent
variables (indicators) contribute to the effect of the intervention.
The primary analysis will be repeated for the t2 assessment (12
months after randomisation) and also using the per-protocol
population to confirm the overall study results. All tests will be
performed two-sided, and P-values < 0.05 will be considered
statistically significant.
Secondary Endpoints
All secondary study parameters, except for the healthcare
utilisation data, will be analysed similarly to the primary outcome
parameter, except that for the secondary outcome measures we
will correct for multiple testing (Bonferroni adjustments). For the
healthcare utilisation data, the primary analysis will be from a
health and social care cost perspective, with secondary analyses
from a societal perspective.
Gender-Specific Analyses
We will undertake a planned subgroup analysis for the primary
outcome measure, separately for women and men.
Other Study Parameters
Information regarding perceived care coordination and
feasibility of the intervention will be obtained in optional
qualitative interviews. To assure the quality of this multicentre,
multinational, multi-language qualitative study, we will build on
the lessons learned from the CLaSP trial (62), in which many
of the study centres participated, and on recommendations and
experiences described in the literature (63).
Software for qualitative analysis will facilitate data storage,
coding, searching both within and across sites, and participant
groups, retrieving data and recording analytical thinking (e.g.,
NVivo or AtlasTi). The data are linked with the quantitative
data to interpret the change in patients/FCs of the quantitative
outcome measures, their clinical significance, and the impact
of the intervention at two levels (people and context; processes
and tasks), and to identify ways to enhance the intervention
and the processes for wider implementation. Quality appraisal is
addressed through procedures to ensure systematic and rigorous
attention to analysis and reporting.
Data Management
Each investigator will document subject data in his/her own
subject files. These subject files will serve as source data
for the study. Data collected during this study as recorded
on the appropriate source documents will be entered in a
web-based electronic data capture (EDC) system specifically
developed for the study and provided by the clinical research
organisation (CRO) and project partner, Mediolanum Cardio
Research (MCR), Milano, Italy. The e-CRFs will be reviewed
periodically for completeness, consistency, and query status by
the data management personnel of the CRO. Remote monitoring
will be regularly performed by the CRO staff in order to oversee
the progress of the study, completion, and quality of collected
data. The raw sensor data, collected with the PDMonitor devices,
and its processed data are uploaded and pseudonymized stored
at the PD Neurotechnology’s cloud platform.
Harms
All adverse events, adverse reactions, and serious adverse events
or reactions that occurred from the signature of the informed
consent during the whole study duration will be recorded in
the specific section of the e-CRF. Death events due to disease
progression will not be considered as serious adverse event (SAE);
however, data will also be recorded in a specific section of eCRF.
Adverse events will be collected and coded using themost current
version of the Medical Dictionary for Regulatory Activities
(MedDRA). Each adverse event will be categorized by severity
(mild, moderate, severe) and seriousness (serious, non-serious).
The investigator will follow up the outcome of any Adverse
Events (clinical signs, laboratory values or other, etc.) until the
return to normal or consolidation of the patient’s condition. In
the case of any Serious Adverse Event, the patient will be followed
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TABLE 2 | Overview of the assessment schedule and its instruments, to evaluate the (cost-) effectiveness and feasibility of the PD_Pal intervention.
Scales/domains Instruments Application at
T0 T1 T2
Study rater completed, together with the patient
Demographics / social data X
Motor symptoms MDS-UPDRS, part III (47) X
Non-motor symptoms MDS-Non-Motor Rating Scale (MDS-NMS) (48) X X X
Cognition Montreal Cognitive Assessment (MoCA) (49) X
Comorbidity Charlson Comorbidity Index (CCI) (50) X
Care coordination Modified Nijmegen Continuity Questionnaire X X X
(mNCQ) (51)
Interview questions*** X X X
Feasibility of the intervention** Feasibility checklist X
(Serious) adverse events Interview questions X X
Study rater completed, together with the FC
Demographics X
Resource utilisation Resource Utilisation questionnaire (RUD) (52), adapted for PD X X X
[if applicable] Quality of the end-of-life experience of the
patient*
Quality of Dying and Death questionnaire (QoDD) (53) X X
Questionnaires completed by the patient independently
Disease-specific symptoms Edmonton Symptom Assessment Scale for Parkinson’s
Disease (ESAS-PD) (54)
X X
Depression Beck Depression Inventory (BDI-I) (55) X X
Quality of life PDQ-39 (56) X X X
Self-rated health EQ-5D-5L (57) X X X
Palliative-phase symptom severity Integrated Palliative Care Outcome (IPOS) (58) X X X
Experienced quality of care (including the intervention) Short Assessment of Patient Satisfaction (SAPS) (59) X X
Experienced involvement in decision making CollaboRATE (60) X X
Questionnaires completed by the FC independently
Quality of life EQ-5D-5L (57) X X X
PQoL Carer (61) X X X
Study rater competed
ACP documentation Chart review X X X
[if applicable] Place of death: preferred and actual Chart review X X
Interview with patient and FC
Feasibility of the intervention**/*** Interview guide X
Experienced quality of care, quality life, and end-of-life
issues***
Interview guide X
Quantitative motor symptom assessment
Motor symptom assessment*** PDMonitor X X X
*in case the patient dies during follow-up; ** intervention group only; *** Optional element of the study protocol; T0, Baseline after inclusion; T1, 6 months after randomisation (intervention
completed); T2, 12 months after randomisation (long-term follow-up).
up until clinical recovery is complete and laboratory results have
returned to normal, or until progression has been stabilized.
DISCUSSION
The awareness of the possible merits of palliative care
interventions for people with PD is growing (14, 64). However,
we still do not fully understand how to optimally design palliative
care models, and little is known about its potential impact for
this patient population (13). In 2020, two large randomized
controlled trials published the effects of multidisciplinary
palliative care teams, with inconsistent results. The first
one, conducted in American outpatient clinics, evaluated a
multidisciplinary palliative care model for PD patients and
their family caregivers. The patients received palliative care
support in person or by telemedicine sessions, every 3 months
for 12 months. The study showed a modest, but significant
improvement in patients’ quality of life after 6 months, leaving
caregiver burden unchanged. In addition, non-motor symptom
burden, motor symptom severity, completion of advance
directives, caregiver anxiety, and caregiver burden favoured the
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intervention group at 12 months (24). The second study targeted
people with long-term neurological conditions, including PD.
This UK-based study evaluated a short-term palliative care
intervention, using a comprehensive assessment, personalized
care planning, case management, and care coordination, and
advising existing care providers. The intervention lasted 6–8
weeks, with three distinct sessions for the patient and family
caregiver with the multi-professional palliative care teams. After
12 weeks, no change in eight key palliative care symptoms
emerged, although the intervention was associated with lower
healthcare costs (65).
The PD_Pal intervention takes a different approach: instead
of involvement of a multidisciplinary care team, we will assign
a dedicated nurse, who will act as the personal case manager
for the patient and family caregiver. The nurse will lead the
conversations, create a relationship based on mutual trust, and
involve other disciplines whenever needed.We deliberately opted
for an intervention strategy, which combines specific training
of a nurse in relevant areas of knowledge and skills with a
prolonged in-depth support intervention for the patients and
FCs. Throughout the intervention period, the nurses will join
monthly digital meetings to share their experiences and discuss
encountered problems and solutions. The Parkinson Support
workbook is designed as a strategy to increase active engagement
of patients and FCs in the ACP conversations about the future.
Furthermore, the intervention is patient-centred and the patients
will be deciding what will be discussed and when. None of the
(sub)steps within the intervention are obligatory and patients can
also add certain care (coordination) issues that are not included
in the Parkinson Support Plan. To summarize, the PD_Pal model
is advocating active engagement of patients as a key element for
effective palliative care interventions (66).
The COVID-19 pandemic has affected the execution
of the trial, which was planned to start in February 2020.
The pandemic shows the importance of discussing goals
of care, and to revisit or establish advance care plans in
an early phase of the disease. Furthermore, the pandemic
forced us to deploy telehealth solutions for e-consent,
e-scales, and e-delivery of the intervention. The original protocol
already included an option for teleconsultations for the PD_Pal
nurses, as a measure to be inclusive for those patients who would
live too far away from the clinical site for regular face-to-face
visits. Now we anticipate to use a teleconsultation model as a
necessary alternative, leveraging on earlier experiences. A review
of 71 studies (67) concluded that, on the positive side, patients
generally experience more comfort and control at home, leading
to an exclusive digital connectedness between conversation
partners. In contrast, professionals can experience reservations
about addressing painful truths and emotional topics during
teleconsultations as they did not feel sufficiently close. We
will therefore strive for a first face-to-face contact between the
PD_Pal nurse and the patient, before a teleconsultation solution
will be applied. Nevertheless, the pandemic creates a unique
opportunity to learn important lessons about the application of
telehealth solutions in clinical research.
To conclude, studying the impact and feasibility of the
intervention in seven European countries, each with their
own cultural and organisational characteristics, will create a
substantial body of knowledge about the future of palliative care
for people with PD and their family caregivers.
ETHICAL CONSIDERATIONS AND
DISSEMINATION
The PD_Pal study design has been developed following the
indications contained in the Charter of Fundamental Rights of
the European Union. Informed consent will be obtained by each
participant as in the Declaration of Helsinki (2013) and in line
with ethic committee approval of the protocol. None of the steps
within the intervention are obligatory. Patients can indicate they
do (not yet) want to discuss or think about certain topics. All
participants will be able to withdraw their informed consent
to parts or to the overall participation at any point in time.
When participants develop cognitive deficits, together with the
FC, we will evaluate their ability and willingness to continue
participating in the study.
The project results will be disseminated through theMDSTask
Force on Palliative Care, the European Association for Palliative
Care, the European Academy of Neurology, and the European
Parkinson’s disease association. In addition, dissemination will
be accomplished through scientific publication on national
and international journals as well as through participation to
scientific and communication events related to the study topics.
It is also important that the progress and findings are presented to
PD patients and caregivers (usually in regional audiences) and by
publishing lay summaries. PD_Pal will support the open-access
(OA) initiative. OA literature is digital, online, free of charge, and
free of most copyright and licensing restrictions. OA to research
articles both in journals (“gold OA”) and in repositories (“green
OA”) is foreseen.
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